Jazz Pharmaceuticals (JAZZ) Issues FY13 Earnings Guidance
Jazz Pharmaceuticals (JAZZ) updated its FY13 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $5.70-5.90 for the period, compared to the Thomson Reuters consensus estimate of $5.73. The company issued revenue guidance of $805-835 million, compared to the consensus revenue estimate of $809.65 million.
Shares of Jazz Pharmaceuticals (JAZZ) traded up 1.43% during mid-day trading on Tuesday, hitting $56.83. Jazz Pharmaceuticals (JAZZ) has a one year low of $40.38 and a one year high of $60.00. The stock’s 50-day moving average is currently $56.76. The company has a market cap of $3.290 billion and a P/E ratio of 25.31.
Jazz Pharmaceuticals last posted its quarterly earnings results on Tuesday, February 26th. The company reported $1.53 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.41 by $0.12. The company had revenue of $183.70 million for the quarter, compared to the consensus estimate of $183.80 million. During the same quarter last year, the company posted $1.17 earnings per share. Jazz Pharmaceuticals’s revenue was up 120.0% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY13 guidance at $5.70-5.90 EPS. On average, analysts predict that Jazz Pharmaceuticals (JAZZ) will post $4.72 earnings per share for the current fiscal year.
Several analysts have also recently commented on the stock. Analysts at Bank of America initiated coverage on shares of Jazz Pharmaceuticals in a research note to investors on Monday. They set a buy rating and a $74.00 price target on the stock. On a related note, analysts at Lazard Capital Markets reiterated a buy rating on shares of Jazz Pharmaceuticals in a research note to investors on Monday, February 4th. They now have a $87.00 price target on the stock. Finally, analysts at Lazard Capital Markets raised their price target on shares of Jazz Pharmaceuticals from $76.00 to $87.00 in a research note to investors on Friday, January 18th. They now have a buy rating on the stock.
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.